ExpreS2ion Biotech Holding
ExpreS2ion Biotech Holding AB is a Swedish biotechnology holding company built around the ExpreS2 recombinant protein expression platform. Through its operating subsidiary ExpreS2ion Biotechnologies ApS, it develops protein-based vaccine and oncology assets, provides contract research services, and holds interests in collaborative vaccine technology ventures such as AdaptVac.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInternally developed vaccine and oncology assets advanced through discovery, preclinical and clinical stages.
Fee-based protein expression, process development and material supply for external partners.
Licensing of the ExpreS2 platform and transfer of know-how to partners and CDMOs.
Publicly funded and partnered vaccine research in malaria, influenza, Nipah and related areas.
Customers
The company sells primarily to biotechnology and pharmaceutical companies, academic groups, and research consortia that need difficult-to-express proteins or vaccine antigens. Its proprietary pipeline is aimed at clinical and translational development partners in oncology, while its platform services are used by organizations that want expression, optimization, or material supply for discovery and preclinical work.
Buy protein expression, process development and research-grade material for difficult constructs and preclinical programs
Use the ExpreS2 platform for discovery-stage expression work and antigen production
Collaborate on malaria, influenza and Nipah vaccine research using the platform
Engage around ES2B-C001 and other assets as programs move toward clinical evaluation
Receive transferred processes and platform know-how for downstream manufacturing
Strategy
ExpreS2ion’s strategy is to advance ES2B-C001 through early clinical development while preserving ownership of its core oncology asset. At the same time, it uses external collaborations, contract research and platform licensing to demonstrate the versatility of ExpreS2 and share development risk.
The lead oncology asset is the main proprietary value driver and a key source of future partnering optionality
Partnered programs extend the platform into global health areas while reducing internal capital needs
Fee-based work and licensing help monetize the platform beyond a single drug asset
Patents and know-how support differentiation and future partnering leverage
Geography
The group is headquartered in Sweden but its operating business is primarily based in Denmark through ExpreS2ion Biotechnologies ApS at DTU Science Park. Its shareholder base is concentrated in Denmark and Sweden, while research collaborations and development activities extend into broader European and international networks.
Risks
The company is exposed to clinical development risk, financing risk and the possibility that early-stage programs do not generate sufficient data to progress. As a biotech platform company, it also faces patent, regulatory, currency and partner-execution risks, with external funding and collaboration central to the business model.
- Going concern and financing dependenceImpact: CriticalLikelihood: High
Clinical-stage development requires continued external funding before product revenue can support operations
Exposure: Company-wide
- Clinical development failureImpact: HighLikelihood: High
ES2B-C001 and partnered vaccine programs are early-stage and may not produce positive data
Exposure: ES2B-C001 and collaborative pipeline
- Patent and technology protectionImpact: HighLikelihood: Low
The platform’s value depends on proprietary expression methods and related IP
Exposure: ExpreS2 platform and GlycoX-S2
- Geopolitical and funding volatilityImpact: MediumLikelihood: High
International collaboration and investor sentiment can be affected by macro and geopolitical uncertainty
Exposure: Capital access and partner programs
- Currency riskImpact: MediumLikelihood: Medium
Operating costs are mainly in DKK/EUR while reporting is in SEK, with potential USD/GBP exposure as development expands
Exposure: Operating expenses and future clinical spend
Accounting
Judgemental itemsManagement has concluded that material uncertainty exists due to the need for additional funding to finance future operations
Impact: Affects liquidity disclosure, valuation assumptions and investor risk assessment
Fee-based projects and partner-funded research may be recognized over time or at milestones depending on contract terms
Impact: Can shift revenue between periods
Reporting currency is SEK while most operating costs are in DKK and EUR
Impact: Can create translation and transaction gains or losses
Clinical and platform development spending may be expensed or capitalized depending on accounting policy and criteria
Impact: Affects operating loss and asset base
The company has had changing share counts and listed equity financing activity
Impact: Impacts per-share metrics and dilution analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Evaxion A/S
EVAX · Biological Products, (No Diagnostic Substances)
Evaxion A/S is a clinical-stage biotech company focused on developing vaccines and other drug candidates using its AI-Immunology™ platform.
Silexion Therapeutics Corp
SLXNW · Biological Products, (No Diagnostic Substances)
Silexion Therapeutics Corp is a U.S.-listed holding company whose operations are conducted primarily through its subsidiary Silexion, a clinical-stage…
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Abpro Holdings, Inc.
ABPWW · Biological Products, (No Diagnostic Substances)
SynAct Pharma
SYNACT · Health Care
SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system.
Hansa Biopharma
HNSA · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Last updated: 24/09/2026